Figure 4

Flow diagram of patients included in this study. From an existing cohort of patients with pathologically proven pancreatic adenocarcinoma from 2013 to 2016, a total of 137 patients who underwent upfront surgery and successful R0 resection were eligible for the final analysis. FDG-PET, 18F-fluoro-2-deoxyglucose-positron emission tomography.